Eikon Therapeutics, Inc. Common Stock
EIKN
Get informed when a big investor buys or sells
+ FollowMarket Cap$28.83M
Close$
$-2.82
131.6% downside
Current Fair Value
131.6% downsideOvervalued by 131.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.83 Million |
|---|---|
| Enterprise Value | $122.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.16 |
| Beta | 0.47 |
| Outstanding Shares | 54,138,555 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.26 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 0.89 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 2.09 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.98
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 43.86%▲ 43.86% |
|---|---|
| Total Invested | $251.20M |
| Investors Holding | 52▲ 52.00% |
ESG Score
No data
About Eikon Therapeutics, Inc. Common Stock
484 employees
CEO: Roger Perlmutter Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of pro...